Home Multimedia Exclusive Videos Exclusive VideosMultimedia PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape Thursday, April 21, 2016 Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here. Advertisement Recent Articles January 2021 Annual Meeting Edition Friday, January 15, 2021 This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more. FDA Approves Ponatinib for Chronic-Phase CML Friday, January 15, 2021 The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia... Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma Friday, January 15, 2021 Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple... Selinexor Combination Approved for Patients with Multiple Myeloma Friday, January 15, 2021 The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received... Big Ideas on Burnout: Trainees Propose System-Wide Solutions Friday, January 15, 2021 The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –... Current Issue January 2021 Annual Meeting Edition Friday, January 15, 2021 This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.